Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
EU research call for the development of multimodal predictive biomarkers for chronic non-communicable diseases using established AI methods. Two-stage procedure with deadlines on 13.04.2027 and 22.09.2027.
Discover your potential with AI support
- Find out if this grant matches your project
- Develop your application together with AI
- Get matched with many more suitable grants
Grant criteria
Funding objective
Funding of collaborative research and innovation projects for the development of multimodal, AI-supported predictive biomarkers for the progression and therapeutic response in chronic non-communicable diseases.
Eligible expenses
- Personnel expenses
- Material costs
- Subcontractor services
- Travel expenses
- Equipment and laboratory costs
Non-eligible expenses
- Acquisition of real estate
- Retroactive costs
- Debt settlement
Eligible to apply
- Companies
- Non-profit Organizations
- Educational Institutions
Funding requirements
- Consortium of at least three independent legal entities from three different Member States or associated countries
- Use of established AI methods for the integration of multimodal biomarker data
- Two-stage submission procedure with blind review in Phase 1
Documents required for application
- Project description
- Financing plan
- Ethics self-assessment
- Curricula vitae of key personnel
- Application form HE RIA IA
Evaluation criteria
- Excellence
- Impact
- Quality and efficiency of implementation
Description
The EU research call aims to establish multimodal, AI-supported predictive biomarkers for chronic non-communicable diseases (excluding cancer). Established artificial intelligence methods are to be used to combine clinically utilized and potential biomarker data with longitudinal and real-world data. The objective is to derive reliable prognostic, progression, and therapy response markers that account for the inter- and intrapersonal heterogeneity of complex disease patterns. An interdisciplinary consortium of at least three legally independent participants from three different EU member states or associated countries is to advance the identification, validation, and clinical testing of the biomarkers. In addition to a detailed integration strategy for molecular, cellular, and digital parameters, a strong focus on trustworthy AI, data protection, and performance metrics is mandatory. The project duration is a maximum of 36 months with a funding rate of 100% and a funding range of €6 million to €8 million. Eligible expenses include personnel, equipment, laboratory costs, material and travel expenses, as well as subcontractor services.
The two-stage submission process begins with the abstract phase (deadline: 13.04.2027), followed by the full proposal phase (deadline: 22.09.2027). A single-blind review initially assesses excellence and impact before the implementation is evaluated in the main procedure. Eligible applicants include companies of all sizes, non-profit organizations, and educational institutions with a European orientation. Clinical researchers, biomedical and AI developers, as well as industry partners and SMEs benefit from the 100% funding for the development of personalized medicine solutions. A comprehensive exploitation and regulatory plan ensures subsequent market launch and approval. Project outlines, financial plans, ethics self-assessments, key personnel CVs, as well as the application form HE RIA/IA are mandatory attachments.